|Bid||22.20 x 1000|
|Ask||22.40 x 1100|
|Day's range||21.01 - 22.62|
|52-week range||10.76 - 40.91|
|Beta (5Y monthly)||2.24|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Aug 1996|
|1y target est||N/A|
Over the past year, shares of CEL-SCI (NYSEMKT: CVM), one of the most shorted companies in the biotech industry, have gone up 70% as the Reddit community r/WallStreetBets began speculating about its potential to launch a new head and neck cancer treatment. There is even a website called killcvmshorts.com with step-by-step instructions on orchestrating a squeeze against those betting on CEL-SCI's failure. At the same, Geert Kersten, the company's CEO, has been engaging in verbal showdowns with those who dare to criticize CEL-SCI's technology on Twitter.
Blood clot concerns lack context, experts say, putting pressure on federal agencies to unpause J&J vaccinations.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...